Managements and Outcomes of Hospitalized Heart Failure Patients with Paroxysmal vs. Nonparoxysmal Atrial Fibrillation in Taiwan.

BACKGROUND: The prognostic significance and the optimal treatment strategy for patients with atrial fibrillation (AF) with heart failure (HF) remain controversial.

METHODS: We extracted data from a large prospective national database involving Taiwanese patients with AF who were hospitalized for acute HF with reduced ejection fraction. Baseline characteristics, AF types, medications, and 1-year outcomes of the patients were analyzed.

RESULTS: At baseline, 393 (26%) patients had AF, including 117 (29.8%) patients with paroxysmal AF (PAF) and 276 (70.2%) with nonparoxysmal AF (N-PAF). Patients with PAF were more likely to have ischemic cardiomyopathy (47.3% vs. 29.7%, p=0.021) and chronic kidney disease (46.2% vs. 29.0%, p=0.001) and higher CHA2DS2-VASc score (4.0 vs. 3.6, p=0.033) compared with patients with N-PAF; however, patients with N-PAF had larger left atrial diameter (50.5 vs. 47.3 mm, p=0.004) than patients with PAF. Patients with PAF were more likely to receive treatment with amiodarone (31.6% vs. 13.8%, p<0.001) and antiplatelet agents (54.1% vs. 42.5%, p=0.041) but less likely to receive treatment with renin-angiotensin system blockers (52.3% vs. 64.9%, p=0.021) and anticoagulants (33.3% vs. 50%, p=0.003) compared with patients with N-PAF at discharge. The 1-year mortality (26.2% vs. 16.5%, p=0.024) and non-HF-related death rates (13.1% vs. 5%, p=0.005) were significantly higher in patients with PAF, whereas HF and arrhythmic death rates were similar in both groups (13.1% vs. 11.5%).

CONCLUSION: Among patients with HF complicated with AF, those with PAF were more likely to receive antiarrhythmic agents, less likely to receive guideline-recommended therapy, but developed worse 1-year outcome compared with patients with N-PAF. These findings further emphasize the importance of optimal guideline-recommended medical therapy in patients with HF.This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/).